Polyvalent vaccines: High-maintenance heroes.

about

Activation-induced Markers Detect Vaccine-Specific CD4⁺ T Cell Responses Not Measured by Assays Conventionally Used in Clinical Trials Recent advances in understanding rhinovirus immunity

P2860

Q57078159-EDA70E85-65B8-4E8B-9214-AA0F298A276F Q57821649-36BAC69F-6275-4C2E-BC0F-5EF11F3CEEFD

P2860

Polyvalent vaccines: High-maintenance heroes.

Item

http://www.wikidata.org/entity/Q55091602

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Polyvalent vaccines: High-maintenance heroes.

@en

Polyvalent vaccines: High-maintenance heroes.

@nl

type

Item

label

Polyvalent vaccines: High-maintenance heroes.

@en

Polyvalent vaccines: High-maintenance heroes.

@nl

prefLabel

Polyvalent vaccines: High-maintenance heroes.

@en

Polyvalent vaccines: High-maintenance heroes.

@nl

P1476

Polyvalent vaccines: High-maintenance heroes

@en

P2093

Barbara Schlingmann

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Vaccination greatly reduces disease, disability, death and inequity worldwide

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

Combination vaccines: issues in evaluation of effectiveness and safety.

The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.

The ABCs of rhinoviruses, wheezing, and asthma

Vaccine production, distribution, access, and uptake.

Pneumococcal vaccines: an update on current strategies.

Hijacking bacterial glycosylation for the production of glycoconjugates, from vaccines to humanised glycoproteins

Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?

P304

e1006904

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PPAT.1006904

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christopher C. Stobart

Katelyn R Castiglia

Martin L Moore

P5008

ScienceSource

P577

2018-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29621336

http://www.w3.org/2001/XMLSchema#string

P921

infection

infectious disease

recombinant protein

P932

5886581

http://www.w3.org/2001/XMLSchema#string

Polyvalent vaccines: High-maintenance heroes.

about

P2860

P2860

Polyvalent vaccines: High-maintenance heroes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P304

P31

P356

P433

P478

P50

P5008

P577

P698

P921

P932